Multiple Sclerosis and Related Disorders

Papers
(The H4-Index of Multiple Sclerosis and Related Disorders is 38. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-04-01 to 2024-04-01.)
ArticleCitations
The COVID-19 pandemic and the use of MS disease-modifying therapies133
COVID-19 in a MS patient treated with ocrelizumab: does immunosuppression have a protective role?127
Multiple sclerosis following SARS-CoV-2 infection121
B-cell depleting therapies may affect susceptibility to acute respiratory illness among patients with multiple sclerosis during the early COVID-19 epidemic in Iran118
Anti-CD20 and COVID-19 in multiple sclerosis and related disorders: A case series of 60 patients from Madrid, Spain110
Treatment of MOG-IgG-associated disorder with rituximab: An international study of 121 patients109
Effects of MS disease-modifying therapies on responses to vaccinations: A review.103
How does the COVID-19 cause seizure and epilepsy in patients? The potential mechanisms99
Adamantanes might be protective from COVID-19 in patients with neurological diseases: multiple sclerosis, parkinsonism and cognitive impairment85
Willingness to obtain COVID-19 vaccination in adults with multiple sclerosis in the United States78
A case of possible atypical demyelinating event of the central nervous system following COVID-1975
The ocrelizumab phase II extension trial suggests the potential to improve the risk: Benefit balance in multiple sclerosis.72
Evaluation of the rate of COVID-19 infection, hospitalization and death among Iranian patients with multiple sclerosis69
Neuromyelitis optica spectrum disorder after presumed coronavirus (COVID-19) infection: A case report68
Neuro-Behcet's disease: An update on diagnosis, differential diagnoses, and treatment64
Severe COVID-19 infection in a patient with multiple sclerosis treated with fingolimod63
Anxiety and depression in Multiple Sclerosis (MS): Antecedents, consequences, and differential impact on well-being and quality of life62
The underpinning biology relating to multiple sclerosis disease modifying treatments during the COVID-19 pandemic60
COVID-19 and disease-modifying therapies in patients with demyelinating diseases of the central nervous system: A systematic review57
Infections in patients diagnosed with multiple sclerosis: A multi-database study57
Psychological status of patients with relapsing-remitting multiple sclerosis during coronavirus disease-2019 outbreak56
Impact of the COVID-19 pandemic on the health care of >1,000 People living with multiple sclerosis: A cross-sectional study55
Negative SARS-CoV-2 antibody testing following COVID-19 infection in Two MS patients treated with ocrelizumab53
Can coronavirus disease 2019 (COVID-19) trigger exacerbation of multiple sclerosis? A retrospective study51
COVID-19 in ocrelizumab-treated people with multiple sclerosis50
Long COVID or post COVID-19 syndrome49
COVID-19 in 7 multiple sclerosis patients in treatment with ANTI-CD20 therapies49
Genetic Acute Necrotizing Encephalopathy Associated with RANBP2: Clinical and Therapeutic Implications in Pediatrics48
COVID-19 in persons with multiple sclerosis treated with ocrelizumab – A pharmacovigilance case series46
Interleukin-6 inhibition with tocilizumab for relapsing MOG-IgG associated disorder (MOGAD): A case-series and review46
MOG-associated encephalitis following SARS-COV-2 infection46
A literature review of cost-of-illness studies on the economic burden of multiple sclerosis.44
COVID-19 vaccine hesitancy in adults with multiple sclerosis in the United States: A follow up survey during the initial vaccine rollout in 202143
Latin American consensus recommendations for management and treatment of neuromyelitis optica spectrum disorders in clinical practice43
Effect of video-based exergaming on arm and cognitive function in persons with multiple sclerosis: A randomized controlled trial41
Prodromal headache in MOG-antibody positive optic neuritis41
Clinical Features of Late-Onset Multiple Sclerosis: a Systematic Review and Meta-analysis40
Covid-19 in a patient with multiple sclerosis treated with natalizumab: May the blockade of integrins have a protective role?40
The Symbol Digit Modalities Test (SDMT) is sensitive but non-specific in MS: Lexical access speed, memory, and information processing speed independently contribute to SDMT performance38
Neuropsychiatric and cognitive effects of the COVID-19 outbreak on multiple sclerosis patients38
Seizures and myelin oligodendrocyte glycoprotein (MOG) antibodies: Two paradigmatic cases and a review of the literature38
The effect of aquatic physical therapy on patients with multiple sclerosis: A systematic review and meta-analysis38
0.090631008148193